Poster List
P01
CAR-T cells
D Sanchez-Martinez
Josep Carreras Leukemia Research Institute; Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III (ISCII) (RICORS, RD21/0017/0029)
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia
P02
CAR-T cells
C Bueno
Josep Carreras Leukemia Research Institute. Campus Clinic. Barcelona. Spain; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC), ISCIII, Madrid, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain.
CD34⁺CD19⁻CD22⁺ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies
P03
CAR-T cells
B Blanco
Instituto de Investigación Hospital 12 de Octubre (i+12); Hospital Universitario 12 de Octubre; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III
Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers
P04
CAR-T cells
M Tristán-Manzano
LentiStem Biotech
Physiological (TCR-like) regulated lentiviral vectors: a platform for the generation of improved CAR-T cells
P05
CAR-T cells
L García-García
Laboratorio de investigación en Oncohematología, Fundación de Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, 28009, Spain
Use of anti-GD2 (Dinutuximab) as a target for CAR-T cells immunotherapy in Neuroblastoma
P06
CAR-T cells
B Díez
Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
Transposon-based CAR-T cells for lymphoma treatment
P07
CAR-T cells
M Cortijo-Gutiérrez
GENyO
Creation of next generation CAR-T by Repurposing endogenous immune pathways
P08
CAR-T cells
A López
CIEMAT/CIBERER
Generation of CAR-T cells for the treatment of squamous cell carcinomas in Fanconi anemia patients
P09
CAR-T cells
P Justicia-Lirio
GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; LentiStem Biotech
Development of 4th generation regulated CAR-T cells (iTRUCKs) targeting pancreatic solid tumors
P10
CAR-T cells
K Pavlovic
GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; Instituto Maimónides de Investigación Biomédica de Córdoba
TCR/HLA-I double knockout CAR-T cells maintain lytic ability with reduced allogenicity
P11
CAR-T cells
P Garcia-Rodriguez
Instituto de Salud Carlos III
Challenges of CAR-T cells in solid tumours: modelling immunotherapy with 3D osteosarcoma cultures
P12
CAR-T cells
P Barbao
IDIBAPS
Chronic antigen exposure induces CAR-T cell loss of function and a dysregulated gene expression profile leading to treatment failure in solid tumors